uniQure price target lowered to $45 from $65 at RBC Capital

RBC Capital lowered the firm’s price target on uniQure (QURE) to $45 from $65 and keeps an Outperform rating on the shares after the company announced that the FDA “essentially changed their mind” for Huntington’s and no longer believes that three-year data presented a few weeks ago may be adequate for approval. While the news is “clearly disappointing,” the firm believes the “final chapter has yet to be written,” though it has lowered its view of the probability of success to 50% from 75%.